FDA Approves Elzonris (tagraxofusp)- the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy
Shots:
- The approval is based on the STML-401-0114 (NCT 02113982) study assessing immunophenotypic diagnostic CD123- CD4 & CD56 patients in treatment-naïve and previously-treated patients IV
- STML-401-0114 results: Elzonris(12 mcg/kg/day): ORR 90% (26/29); CR/CRc 72% (21/29); 45% of patients went for SCT post Elzonris treatment
- Elzonris is a CD123-targeted therapy indicate to treat adult and pediatric patients with both treatment-naïve and previously-treated BPDCN and has also received FDA’s BTD and ODD with its BLA under review by the US FDA
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
